TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today
Bed Bath & Beyond Inc’s (NASDAQ: BBBY) stock plummeted Thursday afternoon following a company filing stating that it does not have enough cash to meet its credit obligations.